Zobrazeno 1 - 10 of 2 138 pro vyhledávání: '"Pierce RH"'
1
Akademický článek
Phase 1 Study of ROR1 Specific CAR T Cells in Advanced Hematopoietic and Epithelial Malignancies.
Autor: Jaeger-Ruckstuhl CA; Fred Hutchinson Cancer Center, Seattle, Washington, United States., Specht JM; University of Washington, Seattle, Washington, United States., Voutsinas JM; Fred Hutchinson Cancer Center, Seattle, WA, United States., MacMillan HR; Fred Hutchinson Cancer Center, Seattle, Washington, United States., Wu QV; Fred Hutchinson Cancer Center, Seattle, WA, United States., Muhunthan V; Fred Hutchinson Cancer Center, Seattle, Washington, United States., Berger C; Fred Hutchinson Cancer Center, Seattle, WA, United States., Pullarkat S; Fred Hutchinson Cancer Center, Seattle, Washington, United States., Wright JH; Fred Hutchinson Cancer Center, Seattle, Washington, United States., Yeung CCS; Fred Hutchinson Cancer Center, Seattle, WA, United States., Hyun TS; Fred Hutchinson Cancer Center, Seattle, WA, United States., Seaton B; Fred Hutchinson Cancer Center, Seattle, Washington, United States., Aicher LD; Fred Hutchinson Cancer Center, Seattle, Washington, United States., Song X; Fred Hutchinson Cancer Center, Seattle, WA, United States., Pierce RH; Brown University, Port Townsend, WA, United States., Lo Y; Fred Hutchinson Cancer Center, Seattle, Washington, United States., Cole GO; Fred Hutchinson Cancer Center, Seattle, Washington, United States., Lee SM; University of Washington, Seattle, WA, United States., Newell EW; Fred Hutchinson Cancer Center, Seattle, United States., Maloney DG; Fred Hutchinson Cancer Center, Seattle, WA, United States., Riddell SR; Fred Hutchinson Cancer Center, Seattle, WA, United States.
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Oct 28. Date of Electronic Publication: 2024 Oct 28.
Zobrazit plný text záznamu
2
Akademický článek
Reversing immunosuppression in the tumor microenvironment of fibrolamellar carcinoma via PD-1 and IL-10 blockade.
Autor: Daniel SK; Department of Surgery, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356410, Seattle, WA, 98195, USA., Sullivan KM; Department of Surgery, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356410, Seattle, WA, 98195, USA., Dickerson LK; Department of Surgery, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356410, Seattle, WA, 98195, USA., van den Bijgaart RJE; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Utria AF; Department of Surgery, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356410, Seattle, WA, 98195, USA., Labadie KP; Department of Surgery, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356410, Seattle, WA, 98195, USA., Kenerson HL; Department of Surgery, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356410, Seattle, WA, 98195, USA., Jiang X; Department of Surgery, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356410, Seattle, WA, 98195, USA., Smythe KS; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Campbell JS; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Pierce RH; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Kim TS; Department of Surgery, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356410, Seattle, WA, 98195, USA., Riehle KJ; Department of Surgery, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356410, Seattle, WA, 98195, USA., Yeung RS; Department of Surgery, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356410, Seattle, WA, 98195, USA., Carter JA; Department of Surgery, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356410, Seattle, WA, 98195, USA., Barry KC; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Pillarisetty VG; Department of Surgery, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356410, Seattle, WA, 98195, USA. vgp@uw.edu.
Publikováno v: Scientific reports [Sci Rep] 2024 Mar 01; Vol. 14 (1), pp. 5109. Date of Electronic Publication: 2024 Mar 01.
Zobrazit plný text záznamu
3
Akademický článek
Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma: A Phase 1 Nonrandomized Controlled Trial.
Autor: Seo YD; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston.; Department of Surgery, University of Washington, Seattle., Lu H; Seagen Inc, Bothell, Washington., Black G; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Smythe K; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Yu Y; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Hsu C; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle., Ng J; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle.; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Hermida de Viveiros P; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Warren EH; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle., Schroeder BA; National Cancer Institute, National Institutes of Health, Bethesda, Maryland., O'Malley RB; Department of Radiology, University of Washington, Seattle., Cranmer LD; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle., Loggers ET; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle., Wagner MJ; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle., Bonham L; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Pillarisetty VG; Department of Surgery, University of Washington, Seattle., Kane G; Department of Radiation Oncology, University of Washington, Seattle., Berglund P; HDT Bio, Seattle, Washington., Hsu FJ; Apexigen, San Carlos, California., Mi X; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Alexiev BA; Department of Pathology, Northwestern University, Chicago, Illinois., Pierce RH; Sensei Biotherapeutics Inc, Boston, Massachusetts., Riddell SR; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Jones RL; Royal Marsden and Institute for Cancer Research, London, UK., Ter Meulen J; Obsidian Therapeutics, Cambridge, Massachusetts., Kim EY; Department of Radiation Oncology, University of Washington, Seattle., Pollack SM; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Publikováno v: JAMA oncology [JAMA Oncol] 2023 Dec 01; Vol. 9 (12), pp. 1660-1668.
Zobrazit plný text záznamu
4
Akademický článek
Conditionally Active, pH-Sensitive Immunoregulatory Antibodies Targeting VISTA and CTLA-4 Lead an Emerging Class of Cancer Therapeutics.
Autor: Smith FD; Sensei Biotherapeutics, Inc., 1405 Research Blvd., Suite 125, Rockville, MD 20850, USA., Pierce RH; 282088 US Highway 101, Port Townsend, WA 98368, USA., Thisted T; Sensei Biotherapeutics, Inc., 1405 Research Blvd., Suite 125, Rockville, MD 20850, USA., van der Horst EH; Sensei Biotherapeutics, Inc., 1405 Research Blvd., Suite 125, Rockville, MD 20850, USA.
Publikováno v: Antibodies (Basel, Switzerland) [Antibodies (Basel)] 2023 Aug 30; Vol. 12 (3). Date of Electronic Publication: 2023 Aug 30.
Zobrazit plný text záznamu
5
Akademický článek
Effects of HLA single chain trimer design on peptide presentation and stability.
Autor: Finton KAK; Division of Basic Science, Fred Hutchinson Cancer Research Center (FHCC), Seattle, WA, United States., Rupert PB; Division of Basic Science, Fred Hutchinson Cancer Research Center (FHCC), Seattle, WA, United States., Friend DJ; Division of Basic Science, Fred Hutchinson Cancer Research Center (FHCC), Seattle, WA, United States., Dinca A; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, United States., Lovelace ES; Division of Basic Science, Fred Hutchinson Cancer Research Center (FHCC), Seattle, WA, United States., Buerger M; Division of Basic Science, Fred Hutchinson Cancer Research Center (FHCC), Seattle, WA, United States., Rusnac DV; Division of Basic Science, Fred Hutchinson Cancer Research Center (FHCC), Seattle, WA, United States., Foote-McNabb U; Division of Basic Science, Fred Hutchinson Cancer Research Center (FHCC), Seattle, WA, United States., Chour W; Institute for Systems Biology, Seattle, WA, United States., Heath JR; Institute for Systems Biology, Seattle, WA, United States., Campbell JS; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, United States., Pierce RH; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, United States., Strong RK; Division of Basic Science, Fred Hutchinson Cancer Research Center (FHCC), Seattle, WA, United States.
Publikováno v: Frontiers in immunology [Front Immunol] 2023 May 03; Vol. 14, pp. 1170462. Date of Electronic Publication: 2023 May 03 (Print Publication: 2023).
Zobrazit plný text záznamu
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
8
Akademický článek
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma.
Autor: Church C; Division of Dermatology, Department of Medicine, University of Washington, Seattle, WA, USA., Pulliam T; Division of Dermatology, Department of Medicine, University of Washington, Seattle, WA, USA., Longino N; Division of Dermatology, Department of Medicine, University of Washington, Seattle, WA, USA., Park SY; Division of Dermatology, Department of Medicine, University of Washington, Seattle, WA, USA., Smythe KS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Makarov V; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Center for Immunotherapy and Precision Immuno-oncology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA., Riaz N; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Jing L; Department of Medicine, University of Washington, Seattle, Washington, USA., Amezquita R; Biostatistics Bioinformatics and Epidemiology Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Campbell JS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Gottardo R; Biostatistics Bioinformatics and Epidemiology Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Lausanne University Hospital, Lausanne, Vaud, Switzerland.; Swiss Institute of Bioinformatics, Lausanne, Switzerland., Pierce RH; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Choi J; Department of Dermatology, Biochemistry & Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Chan TA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Center for Immunotherapy and Precision Immuno-oncology, Cleveland Clinic, Cleveland, Ohio, USA., Koelle DM; Department of Medicine, University of Washington, Seattle, Washington, USA.; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Global Health, University of Washington, Seattle, WA, USA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.; Benaroya Research Institute, Seattle, WA, USA., Nghiem P; Division of Dermatology, Department of Medicine, University of Washington, Seattle, WA, USA pnghiem@uw.edu.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Sep; Vol. 10 (9).
Zobrazit plný text záznamu
9
Akademický článek
Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma.
Autor: Andtbacka RHI; Surgical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., Wang Y; X4 Pharmaceuticals, Boston, Massachusetts., Pierce RH; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Campbell JS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Yushak M; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia., Milhem M; Medical Oncology, University of Iowa, Iowa City, Iowa., Ross M; Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, Texas., Niland K; X4 Pharmaceuticals, Boston, Massachusetts., Arbeit RD; X4 Pharmaceuticals, Boston, Massachusetts., Parasuraman S; X4 Pharmaceuticals, Boston, Massachusetts., Bickley K; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Yeung CC; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Aicher LD; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Smythe KS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Gan L; X4 Pharmaceuticals, Boston, Massachusetts.
Publikováno v: Cancer research communications [Cancer Res Commun] 2022 Aug 31; Vol. 2 (8), pp. 904-913. Date of Electronic Publication: 2022 Aug 31 (Print Publication: 2022).
Zobrazit plný text záznamu
10
Akademický článek
An In Vivo Model of Human Macrophages in Metastatic Melanoma.
Autor: Voillet V; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.; Cape Town HIV Vaccine Trials Network Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town, South Africa., Berger TR; Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., McKenna KM; Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Graduate Program in Molecular and Cellular Biology, University of Washington, Seattle, WA.; Medical Scientist Training Program, University of Washington, Seattle, WA., Paulson KG; Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Tan WH; Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Smythe KS; Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Hunter DS; Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Valente WJ; Graduate Program in Molecular and Cellular Biology, University of Washington, Seattle, WA.; Medical Scientist Training Program, University of Washington, Seattle, WA.; Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA.; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA., Weaver S; Experimental Histopathology, Fred Hutchinson Cancer Center, Seattle, WA., Campbell JS; Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA., Kim TS; Department of Surgery, University of Washington, Seattle, WA., Byrd DR; Department of Surgery, University of Washington, Seattle, WA., Bielas JH; Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA.; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA., Pierce RH; Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Chapuis AG; Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Medicine, University of Washington, Seattle, WA., Gottardo R; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.; Department of Biostatistics, University of Washington, Seattle, WA; and., Rongvaux A; Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA; rongvaux@fredhutch.org.; Department of Immunology, University of Washington, Seattle, WA.
Publikováno v: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2022 Aug 01; Vol. 209 (3), pp. 606-620. Date of Electronic Publication: 2022 Jul 11.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje